azathioprine 50 MG Oral Tablet [Imuran]

Verify with CMS →

azathioprine

RxCUI: 105611

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
1.6%
Plan Coverage
82
Plans Covering
T3
Avg Tier
100%
Prior Auth Required

What the CMS Formulary Data Shows for azathioprine 50 MG Oral Tablet [Imuran]

Per the CMS 2026 Part D formulary file, azathioprine 50 MG Oral Tablet [Imuran] (RxNorm concept RXCUI 105611, generic name azathioprine) appears on 3 distinct formulary files spanning 82 Medicare Part D plan offerings - 1.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.

Real-world access to azathioprine 50 MG Oral Tablet [Imuran] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 90,745 Part D beneficiaries filled azathioprine 50 MG Oral Tablet [Imuran] in 2023, with total plan-and-beneficiary spending of $27,502,293 and an average per-beneficiary annual cost of $303.07. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry azathioprine 50 MG Oral Tablet [Imuran] today.

Coverage Details

Formularies covering
3
Plans covering
82
Coverage rate
1.6%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
90,745
Total spending
$27,502,293
Avg per beneficiary
$303.07

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic
80 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering azathioprine 50 MG Oral Tablet [Imuran]

82 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 Yes $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 Yes $34.50 NY
Óptimo Plus (PPO) TRIPLE S ADVANTAGE, INC. T4 Yes $0 PR
Contigo Plus (HMO C-SNP) TRIPLE S ADVANTAGE, INC. T4 Yes $0 PR
Brillante (HMO-POS) TRIPLE S ADVANTAGE, INC. T4 Yes $0 PR
Enlace Plus (HMO) TRIPLE S ADVANTAGE, INC. T4 Yes $0 PR
ContigoEnMente (HMO C-SNP) TRIPLE S ADVANTAGE, INC. T4 Yes $0 PR
Ahorro Plus (HMO) TRIPLE S ADVANTAGE, INC. T4 Yes $0 PR
SCAN Connections (HMO D-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Connections at Home (HMO D-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN NEVADA, INC. T4 Yes $0 NV
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN NEVADA, INC. T4 Yes $0 NV
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN NEVADA, INC. T4 Yes $0 NV
SCAN MyChoice (HMO) SCAN HEALTH PLAN NEVADA, INC. T4 Yes $0 NV
SCAN Classic (HMO) SCAN DESERT HEALTH PLAN, INC. T4 Yes $0 AZ
SCAN Balance (HMO C-SNP) SCAN DESERT HEALTH PLAN, INC. T4 Yes $0 AZ
SCAN Embrace (HMO-POS I-SNP) SCAN DESERT HEALTH PLAN, INC. T4 Yes $0 AZ
SCAN Strive (HMO C-SNP) SCAN DESERT HEALTH PLAN, INC. T4 Yes $0 AZ
SCAN MyChoice (HMO) SCAN DESERT HEALTH PLAN, INC. T4 Yes $0 AZ
SCAN Classic WA (HMO) SCAN HEALTH PLAN (WA) T4 Yes $0 WA
SCAN MyChoice WA (HMO) SCAN HEALTH PLAN (WA) T4 Yes $0 WA
SCAN Classic (HMO) SCAN HEALTH PLAN (NM) T4 Yes $0 NM
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN (NM) T4 Yes $0 NM
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN (NM) T4 Yes $0 NM
SCAN MyChoice (HMO) SCAN HEALTH PLAN (NM) T4 Yes $0 NM
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Prime (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Balance (HMO C-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Alta (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Venture (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Venture (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Embrace (HMO I-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Embrace (HMO I-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Embrace (HMO-POS I-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Affirm partnered with Included LGBTQ+ Health (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Affirm partnered with Included LGBTQ+ Health (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Strive (HMO C-SNP) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Inspired by women for women (HMO) SCAN HEALTH PLAN T4 Yes $0 CA
SCAN Classic (HMO) SCAN HEALTH PLAN T4 Yes $0 CA

Frequently Asked Questions

Is azathioprine 50 MG Oral Tablet [Imuran] covered by Medicare Part D?

Yes, azathioprine 50 MG Oral Tablet [Imuran] is covered by 82 Medicare Part D plans (1.6% of all Part D formularies).

What tier is azathioprine 50 MG Oral Tablet [Imuran] on Medicare Part D plans?

azathioprine 50 MG Oral Tablet [Imuran] averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 4.

Does azathioprine 50 MG Oral Tablet [Imuran] require prior authorization?

100% of Part D formularies require prior authorization for azathioprine 50 MG Oral Tablet [Imuran]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on azathioprine 50 MG Oral Tablet [Imuran]?

In 2023, total Medicare Part D spending on azathioprine 50 MG Oral Tablet [Imuran] was $27,502,293, covering 90,745 beneficiaries. The average spend per beneficiary was $303.07.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial